Stockscreener 앱 받기
1.48
1.99%
-0.03
시간 외 거래:
1.50
0.02
+1.35%
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan
Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - TipRanks
InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView
Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com
InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo
InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK
InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan
InMed Pharmaceuticals (INM) Shares Slide Over 3% as Biotech Volatility IntensifiesInstitutional Flow Picks - newsline.com
InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate
INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals and Mentari Announce Merger AgreementThe Legal Advocate - The Legal Advocate
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²
Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter
InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus
Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.
Mentari, InMed Merge In Deal Backed By $290M Funding - Law360
InMed Pharmaceuticals, Inc. (INM) Stock: Climbs on $290M Private Placement and Migraine Pipeline Deal - parameter.io
InMed Pharmaceuticals and Mentari Therapeutics Announce $290M Merger to Advance Migraine Prevention Therapies - Minichart
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
InMed amends warrant terms, cuts exercise price to $0.80 - Investing.com UK
InMed Soars 100% on $290M Migraine Deal - TechStock²
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development - GuruFocus
Trending Stocks Today | Amesite Surges 150.6% - Moomoo
2.11%
자본화:
|
볼륨(24시간):